GBM, short for glioblastoma multiforme, is the most common and aggressive form of brain cancer in adults. It is classified as a grade 4 tumor, the highest grade on the World Health Organization’s scale, meaning it grows rapidly and infiltrates surrounding brain tissue. Median survival after diagnosis is roughly 9 to 15 months with standard treatment, though newer therapies are pushing that number higher for some patients.
How GBM Differs From Other Brain Tumors
Glioblastoma arises from star-shaped brain cells called astrocytes that support nerve function. What sets it apart from lower-grade brain tumors is its speed, its ability to recruit new blood vessels to fuel its growth, and the areas of dead tissue (necrosis) that form at its core as the tumor outpaces its own blood supply. Under a microscope, pathologists look for two hallmark features: clusters of new, abnormal blood vessels and rings of tumor cells surrounding dead tissue.
The 2021 WHO classification also requires molecular testing. To officially qualify as a glioblastoma, the tumor must lack mutations in a gene called IDH. About 90% of glioblastomas fall into this “IDH-wildtype” category. The roughly 10% of grade 4 tumors that do carry an IDH mutation are now classified separately as grade 4 astrocytomas, because they behave differently and respond differently to treatment. Patients with IDH-mutant tumors survive roughly twice as long (around 31 months versus 15 months on average).
Common Symptoms
Symptoms depend on where in the brain the tumor develops, but the most frequent early sign is a headache that doesn’t fit a person’s normal pattern. These headaches tend to be worse in the morning, worsen when lying down, and may come with nausea or vomiting. That pattern reflects rising pressure inside the skull as the tumor and surrounding swelling take up space.
Beyond headaches, glioblastoma can cause:
- Seizures in someone with no prior seizure history
- Cognitive changes like difficulty finding words, confusion, or trouble concentrating
- Vision problems including blurred or double vision and loss of peripheral vision
- Weakness or numbness on one side of the body
- Personality or mood shifts such as increased irritability, restlessness, or emotional flatness
- Increasing fatigue or sleepiness that doesn’t improve with rest
Because these symptoms overlap with many less serious conditions, glioblastoma is sometimes misdiagnosed early on as migraines, stress, or depression. Symptoms typically progress over weeks to a few months before the tumor is identified.
How GBM Is Diagnosed
The key diagnostic tool is an MRI with contrast dye. Glioblastomas have a distinctive appearance: a bright, irregularly enhancing ring around a dark necrotic center, often surrounded by a halo of brain swelling. The tumor’s aggressive blood vessels are leaky, so they absorb contrast dye heavily, lighting up on the scan. A higher degree of enhancement generally correlates with a higher-grade tumor.
Imaging alone can strongly suggest glioblastoma, but a tissue sample from surgery or biopsy confirms the diagnosis. Pathologists then run molecular tests, including IDH mutation status and a test called MGMT promoter methylation, which helps predict how well the tumor will respond to chemotherapy. Patients whose tumors have MGMT methylation (around 55% of IDH-wildtype glioblastomas) tend to benefit more from standard chemotherapy.
Standard Treatment
Treatment for newly diagnosed glioblastoma follows a well-established sequence: surgery first, then radiation combined with chemotherapy, then chemotherapy alone for several additional cycles. This approach, known as the Stupp protocol after the researcher who established it in 2005, remains the backbone of GBM care.
Surgery aims to remove as much of the visible tumor as possible while preserving brain function. When surgeons can remove more than 98% of the tumor volume, survival ranges from roughly 52 to 86 weeks. When resection is less complete, survival drops to 35 to 64 weeks. However, because glioblastoma infiltrates surrounding tissue at a microscopic level, surgery alone cannot cure it. Invisible tumor cells always remain.
After surgery, patients typically receive six weeks of daily radiation (a total dose of 60 Gy) alongside daily oral chemotherapy. This is followed by six additional monthly cycles of chemotherapy taken five days at a time. The entire post-surgical treatment course spans about nine months.
Tumor Treating Fields
A newer addition to the standard approach is a wearable device that delivers low-intensity electrical fields to the scalp, designed to disrupt tumor cell division. In a large randomized trial, adding this device to chemotherapy after radiation improved median survival from 16.0 months to 20.9 months and nearly doubled the five-year survival rate. Real-world data from multiple hospitals confirmed the benefit, showing a consistent 4 to 5 month improvement in overall survival. The device requires wearing electrode arrays on a shaved scalp for at least 18 hours a day, which is a significant lifestyle commitment that patients weigh against the survival benefit.
Why GBM Almost Always Comes Back
Despite aggressive treatment, glioblastoma recurs in the vast majority of patients. The median time from initial treatment to recurrence is approximately one year. Recurrence happens because microscopic tumor cells embed themselves deep in normal brain tissue where surgery and radiation cannot reach them, and these cells are often genetically diverse enough that some survive chemotherapy.
When the tumor returns, options include a second surgery, re-irradiation, and different chemotherapy drugs. An oral chemotherapy called lomustine is one of the most commonly used treatments for recurrent disease and has been a standard option since 1976. An anti-angiogenic drug that cuts off the tumor’s blood supply is also FDA-approved for recurrent glioblastoma. It can reduce swelling and improve symptoms, though its effect on overall survival remains debated. A portable electrical field device is also approved for recurrent cases.
Survival and Prognosis
Population-level data shows that outcomes have improved over the past two decades, with median survival rising from about 6.4 months to 9.4 months and two-year survival rates climbing from 10% to 18%. With the full modern treatment regimen including tumor treating fields, median survival for clinical trial patients reaches roughly 20 to 22 months. These numbers represent medians, meaning half of patients live longer. A small but real percentage of patients survive five years or more, particularly those with favorable molecular markers like MGMT methylation and younger age at diagnosis.
Several factors influence individual prognosis. Younger patients fare better than older ones. Tumors with MGMT methylation respond more strongly to chemotherapy. The extent of surgical removal matters. And overall health and functional status at diagnosis play a significant role in how well someone tolerates treatment.
Experimental Therapies Being Tested
One of the most actively studied approaches is a type of immune cell therapy where a patient’s own immune cells are engineered to recognize and attack tumor cells. Early-phase trials are testing different versions of this therapy delivered directly into the brain rather than through the bloodstream, since intravenous approaches showed limited ability to penetrate the tumor. In one trial of 65 patients, half achieved disease control, and about 23% survived at least one year. A small trial of three patients using a dual-target approach saw all three respond initially. These results are early and involve small numbers, but they represent the first clear signs that engineered immune cells can produce measurable, if often temporary, responses against glioblastoma.
The central challenge with glioblastoma is its heterogeneity. Individual tumors contain cells with different genetic profiles, so a therapy that kills one population may leave others unaffected. This is why multi-target approaches and combination strategies are a major focus of current research.